ClinicalTrials.gov
ClinicalTrials.gov Menu

The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis (LongPAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03531996
Recruitment Status : Recruiting
First Posted : May 22, 2018
Last Update Posted : May 22, 2018
Sponsor:
Collaborators:
Rare Diseases Clinical Research Network
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Bruce Trapnell, Children's Hospital Medical Center, Cincinnati

Brief Summary:
The major goal of this study is to conduct a prospective, longitudinal study of autoimmune PAP to examine outcome measures for disease severity of potential use in clinical practice and/or clinical research studies. These results will impact the field by: 1) improving an understanding of the clinical course of autoimmune PAP, 2) providing information on various clinical outcome and quality of life outcome measures to guide patients and physicians in making treatment choices, and 3) facilitate the development of pharmaco-therapeutics for autoimmune PAP and 4) better informing PAP researchers.

Condition or disease
Autoimmune Pulmonary Alveolar Proteinosis

Detailed Description:
PAP is a rare syndrome of surfactant accumulation and resulting hypoxemic respiratory failure that occurs in a number of diseases classified pathogenically into three groups: primary PAP (caused by disruption of GM-CSF signaling - autoimmune PAP, hereditary PAP), secondary PAP (caused by reduction in alveolar macrophage numbers and/or functions), and surfactant dysfunction-related PAP (caused by mutations in genes required for normal surfactant production). In current clinical practice, PAP is diagnosed based on a lung biopsy; an approach that is not able to identify the PAP-causing disease in anyone. Current therapy involves the physical removal of surfactant by a procedure in which the lungs are repeatedly filled with saline and emptied - whole lung lavage, which is invasive, inefficient, and not widely available, especially for children. Importantly, research advances have elucidated the pathogenesis of diseases causing PAP in most patients and have identified new diagnostic and therapeutic approaches. Simple blood-based research tests can now identify the PAP-causing disease in about 95% of patients. Further, several promising potential disease-specific therapies are currently in development. The long-term goals of the Rare Lung Diseases Consortium include improving the diagnosis and therapy of people with PAP. A major goal of this protocol is to conduct a prospective, longitudinal study of autoimmune PAP to examine outcome measures for disease severity for potential use in clinical practice and/or clinical research studies. The investigator's central hypothesis is that a prospective, longitudinal study of autoimmune PAP patients will facilitate the identification of useful outcome measures for use in clinical practice and/or clinical research studies. The specific objectives of the study are to: 1) evaluate blood-based biomarkers of PAP lung disease over time in autoimmune PAP patients, 2) evaluate the natural history/clinical course of autoimmune PAP over time, 3) evaluate quality of life measures over time in autoimmune PAP patients, 4) evaluate physiologic measures of disease over time in autoimmune PAP patients, and 5) evaluate radiologic measures of lung disease progression over time in autoimmune PAP patients. The study design will be observational and will involve recruitment, screening, and enrollment of eligible participants and annual collection of clinical data. The experimental approach will be to assess the rate of change in GM-CSF signaling assay parameters from baseline to 24 months. GM-CSF signaling assay parameters include GM-CSF autoantibody (GMAb) level, pSTAT5-Max, STAT5-phosphorylation index (STAT5-PI), GM-CSF signaling index (GM-SI), and GM-CSF EC50. The study will also assess the progression of autoimmune PAP, including but not limited to use of treatment options, the number and types of infections and other inter-current medical issues with quality of life measures, exercise tolerance, and radiologic imaging. Experimental outcomes will evaluate SP-D, cholestenoic acid, and lipid levels. Anticipated results will establish a natural history/clinical course of autoimmune PAP to better serve patients and providers, to better inform PAP researchers, and validate outcome measures and biomarkers for use in future clinical studies of PAP. These results will impact the field by: 1) improving an understanding of the clinical course of autoimmune PAP, 2) providing information on various clinical outcome and quality of life outcome measures to guide patients and physicians in making treatment choices, and 3) facilitate the development of pharmacotherapeutics for autoimmune PAP and 4) better informing PAP researchers.

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
Actual Study Start Date : April 19, 2018
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Longitudinal evaluation of GM-CSF autoantibody levels [ Time Frame: Baseline, 1 year, and 2 years ]
    Change in GM-CSF autoantibody levels in autoimmune PAP patients over time

  2. Longitudinal evaluation of the maximal phospho-STAT5 level after GM-CSF stimulation [ Time Frame: Baseline, 1 year, and 2 years ]
    Change in phospho-STAT5 levels in autoimmune PAP patients over time

  3. Longitudinal evaluation of the STAT5 Phosphorylation Index [ Time Frame: Baseline, 1 year, and 2 years ]
    Change in the STAT5 phosphorylation index in autoimmune PAP patients over time

  4. Longitudinal evaluation of the GM-CSF Signaling Index [ Time Frame: Baseline, 1 year, and 2 years ]
    Change in GM-CSF signaling index in autoimmune PAP patients over time

  5. Longitudinal evaluation of the dose GM-CSF to stimulation 1/2 maximal STAT5 phosphorylation (EC50) [ Time Frame: Baseline, 1 year, and 2 years ]
    Change in GM-CSF EC50 level in autoimmune PAP patients over time


Secondary Outcome Measures :
  1. Frequency of therapeutic intervention [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the patient's history of a need for therapeutic intervention

  2. Concurrent infections [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the patient's history of concurrent infections

  3. Blood SP-D [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in serum SP-D levels

  4. Blood cholestenoic acid [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in cholestenoic acid levels

  5. Blood lipid levels [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in blood lipid levels

  6. Quality of Life measured by St. George Respiratory Questionnaire [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the overall health, daily life, and perceived well-being in patients with obstructive airways disease. The questionnaire is divided into two parts: Part 1: Symptoms component (frequency & severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall.

  7. Shortness of breath measured by San Diego Dyspnea Score [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the severity of shortness of breath on a 6-point scale (0 = Not at all, 5 = Maximally or unable to do because of breathlessness) during 21 activities of daily living associated with varying levels of exertion. Three additional questions ask about fear of harm from overexertion, limitations, and fear caused by shortness of breath, for a total of 24 items. If patients do not routinely perform an activity, they are asked to estimate their anticipated shortness of breath. A total sum score ranges from 0 to 120.

  8. Minimum SpO2 during a standardized exercise protocol [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the minimum SpO2 during exercise on a scale of 0 to 100. The study will be stopped if the Sp02 reaches 88%.

  9. Time during standardized exercise protocol required for SpO2 to fall below 88% [ Time Frame: Baseline, 1 year, and 2 years ]
    Change over time in the time for the SpO2 to fall below 88% during the standardized exercise protocol while patients step onto and off of a step for 5 minutes.


Biospecimen Retention:   Samples With DNA
Biospecimens retained will be serum, plasma, and DNA.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Pulmonary Alveolar Proteinosis
Criteria

Inclusion Criteria:

  • Written informed consent must be provided by:

    • Participant if at least 18 years old -OR-
    • Parent/legal guardian if participant is less than 18 years old -AND-
    • Participant provides assent when appropriate
  • History of diagnosis of autoimmune as indicated by a:

    • History of chest CT or x-ray findings compatible with PAP -AND-
    • History of a Positive (Abnormal) serum GMAb test

Exclusion Criteria:

  • Individuals who have a serious medical illness that, in the opinion of the investigator, is likely to interfere with completion of the study will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03531996


Contacts
Contact: Brenna Carey, MS, PhD 513-636-6361 Brenna.Carey@cchmc.org

Locations
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Brenna Carey, MS, PhD         
Principal Investigator: Bruce Trapnell, MD         
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Rare Diseases Clinical Research Network
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Study Chair: Bruce Trapnell, MD Children's Hospital Medical Center, Cincinnati

Publications:
Responsible Party: Bruce Trapnell, Principal Investigator, Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03531996     History of Changes
Other Study ID Numbers: 2017-7514
U54HL127672 ( U.S. NIH Grant/Contract )
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: May 22, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Bruce Trapnell, Children's Hospital Medical Center, Cincinnati:
Pulmonary Surfactant
Rare Lung Disease
Registry

Additional relevant MeSH terms:
Pulmonary Alveolar Proteinosis
Autoimmune Diseases
Lung Diseases
Respiratory Tract Diseases
Immune System Diseases